Compare LODE & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | PROF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 247.5M |
| IPO Year | 2004 | 2017 |
| Metric | LODE | PROF |
|---|---|---|
| Price | $2.94 | $7.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.4M | 66.5K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | $1,553,796.00 | ★ $16,098,000.00 |
| Revenue This Year | $1,582.85 | $92.40 |
| Revenue Next Year | $246.20 | $64.10 |
| P/E Ratio | ★ N/A | $36.05 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $2.24 | $3.92 |
| 52 Week High | $4.98 | $8.95 |
| Indicator | LODE | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 29.49 | 61.55 |
| Support Level | $2.58 | $6.43 |
| Resistance Level | $3.45 | $7.93 |
| Average True Range (ATR) | 0.29 | 0.39 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 10.49 | 63.60 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.